BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• Business

  Aeromics and Simcere Announce Collaboration and License Agreement for AER-271 in Greater China

  Simcere will be responsible for the clinical development and commercialization of AER-271 in Greater China.

  November 4, 2019

   · 

  3 min read
• Business

  STERIS Announces Financial Results for Fiscal 2020 Second Quarter

  STERIS plc announced financial results for its fiscal 2020 second quarter ended September 30, 2019.

  November 4, 2019

   · 

  13 min read
• Deals

  Merus N.V. Announces Proposed Underwritten Public Offering of Common Shares

  Merus N.V., a clinical-stage bispecific antibody company developing Biclonics®, announced the launch of a proposed underwritten public offering of up to $60.0 million of its common shares. All of the common shares are being offered by Merus N.V.

  November 4, 2019

   · 

  5 min read
• Business

  Arvinas Reports Third Quarter 2019 Financial Results and Provides Corporate Update

  Presented initial data from the company’s ongoing Phase 1 clinical trials of ARV-110 and ARV-471.

  November 4, 2019

   · 

  11 min read
• Business

  MyoKardia Reports Third Quarter 2019 Financial Results

  Completed Enrollment of 251 Patients in the Phase 3 EXPLORER-HCM Trial

  November 4, 2019

   · 

  12 min read
• Bone Cancer Drugs Market - Advent of Targeted Therapies for the Treatment of Bone Cancer to Boost Growth through 2019-2023 | Technavio

  Technavio has announced its latest market research report titled global bone cancer drugs market 2019-2023

  November 4, 2019

   · 

  3 min read
• Business

  Cognate BioServices announces acquisition of Cobra Biologics

  Transformative acquisition creates global cell and gene therapy manufacturing services platform for both clinical and commercial products

  November 4, 2019

   · 

  5 min read
• FDA

  FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older

  Will be available in fall 2020, in time for the 2020-2021 flu season ac

  November 4, 2019

   · 

  7 min read
• Business

  Taro Provides Results for September 30, 2019

  Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the three and six months ended September 30, 2019.

  November 4, 2019

   · 

  11 min read
• Business

  Ascendis Pharma A/S Announces Third Quarter 2019 Financial Results and Business Update Conference Call on November 18

  A webcast replay will be available on this website shortly after conclusion of the event for 30 days.

  November 4, 2019

   · 

  4 min read